IL-22: A Potent Therapeutic Protein with Multiple Functions (G50616)

Target Name: IL22

NCBI ID: G50616

IL-22: A Potent Therapeutic Protein with Multiple Functions

The IL-22 protein is a cytokine that plays a crucial role in the regulation of immune responses and cell growth. It is a member of the Interleukin-2 family of cytokines, which include IL-1, IL-2, IL-3, and IL-4. IL-22 is produced by T-cells and NK cells in response to an infection or injury and has been shown to have potent immune-modulating effects.

One of the key functions of IL-22 is its ability to stimulate the production of CD4+ T cells. CD4+ T cells are a crucial part of the immune system and are responsible for cell-mediated immunity. They are important for fighting off infections and for Maintaining the overall health of the body. IL-22 has been shown to be a potent stimulator of CD4+ T cell production in both humans and animals.

Another important function of IL-22 is its ability to stimulate the production of natural killer cells (NK cells). NK cells are a type of immune cell that play a key role in fighting off infections and cancer. IL-22 has been shown to be a potent stimulator of NK cell production in both humans and animals.

IL-22 has also been shown to have pro-inflammatory effects. When the body is under attack, IL-22 is produced in response to the infection or injury and helps to stimulate the production of other pro-inflammatory cytokines. This increase in pro -inflammatory cytokines can lead to tissue damage and inflammation. However, IL-22 has also been shown to have anti-inflammatory effects. It can inhibit the production of pro-inflammatory cytokines and reduce tissue inflammation.

IL-22 has been shown to have a variety of potential therapeutic applications. For example, it has been shown to be an effective treatment for a variety of skin cancers, including basal cell carcinoma, squamous cell carcinoma and melanoma. IL-22 has also been shown to be an effective treatment for a variety of autoimmune diseases, including rheumatoid arthritis, autoimmune gastritis and psoriasis.

IL-22 has also been shown to have potential applications in regenerative medicine. For example, IL-22 has been shown to be an effective stimulator of peripheral blood stem cell (PBSC) proliferation and differentiation into functional immune cells, such as T-cells and natural killer cells. This may have potential applications in the development of immune-based therapies for a variety of diseases.

In addition to its potential therapeutic applications, IL-22 is also a drug target. Several studies have shown that IL-22 can be targeted by small molecules and antibodies and that it plays a role in a variety of cellular processes. For example, one study shows that IL-22 can be inhibited by the small molecule drug, PD-L1, which is currently being developed as a cancer therapeutic.

Overall, IL-22 is a protein that has a variety of potential therapeutic applications. Its ability to stimulate CD4+ T cell and NK cell production, as well as its anti-inflammatory and immunomodulatory effects, make it an attractive target for further research and development . Additionally, its potential as a drug target makes it a promising area for future therapeutic development.

Protein Name: Interleukin 22

Functions: Cytokine that plays a critical role in modulating tissue responses during inflammation (PubMed:17204547). Plays an essential role in the regeneration of epithelial cells to maintain barrier function after injury and for the prevention of further tissue damage (PubMed:17204547). Unlike most of the cytokines, has no effect on immune cells. Signals through a heterodimeric receptor composed of two subunits, the specific receptor IL22RA1 which is present on non-immune cells in many organs and the shared subunit IL10RB (PubMed:10875937, PubMed:18599299). Ligation of IL22RA1 with IL22 induces activation of the tyrosine kinases JAK1 and TYK2, which in turn activates STAT3. In turn, promotes cell survival and proliferation through STAT3, ERK1/2 and PI3K/AKT pathways (PubMed:25793261, PubMed:31311100)

More Common Targets